Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback